FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949461999> ?p ?o ?g. }

• W2949461999 abstract "Background Pathological findings of interstitial pneumonia (IP) reveal the accumulation of inflammatory cells and proliferation of fibroblasts in lung tissue. Although a treatment has not yet been established for IP, particularly for IP with collagen diseases, chemokines may play a role in the pathogenesis of IP for inflammatory cell infiltration. We previously reported that chemokine (C-X3-C motif) ligand 1 (CX3CL1, also known as fractalkine) has potential as a therapeutic target for rheumatoid arthritis (RA).1,2,3Humanized anti-human CX3CL1 monoclonal antibody (mAb) is currently undergoing clinical trials for RA.4 Objectives In the present study, we examined the therapeutic effects of CX3CL1 blockade in a murine model of IP. Methods Bleomycin (BLM)-induced IP was developed by the intratracheal administration of BLM to C57BL/6 mice. The murine lung was stained with hematoxylin and eosin, and the expression of CX3CL1 and CX3CR1, a receptor for CX3CL1, was analyzed by immunohistochemistry. Mice were treated with anti-CX3CL1 mAb for 2 weeks. Collagen eluted from the lung was quantified using the SircolTM Collagen Assay. The expression of CX3CL1 and CX3CR1 by mouse lung fibroblasts (MLFs) was examined with quantitative RT-PCR and Western blotting, respectively. Cell movement was investigated using the scrape motility assay. Results The expression of CX3CL1 and CX3CR1 was upregulated in BLM-induced IP. The treatment with anti-CX3CL1 mAb did not significantly alter inflammatory cell infiltration. However, collagen in the lung was decreased by the treatment with anti-CX3CL1 mAb. Stimulation with CX3CL1 did not alter the in vitro production of collagen by MLFs, but significantly enhanced cell movement. Conclusion CX3CL1 may be involved in increasing collagen in IP and the cell movement of MLFs. The present results suggest that CX3CL1 plays an important role in fibrosis in IP. References [1] Nanki T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol. 2004;173(11):7010-6. [2] Nanki T, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(11):2878-83. [3] Nanki T, et al. Fractalkine/CX3CL1 in rheumatoid arthritis. Mod Rheumatol. 2017 May;27(3):392-397. [4] Tanaka Y, et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern rheumatology. 2018;28(1):58-65. Disclosure of Interests Soichi Yamada: None declared, Shion Miyoshi: None declared, Natsuko Kusunoki: None declared, Hiroshi Sato: None declared, Yoshikazu Kuboi Shareholder of: Eisai Co., Ltd., Employee of: KAN Research Institute, Inc. (subsidiary of Eisai Co., Ltd.), Kana Hoshino-Negishi Shareholder of: Eisai Co., Ltd., Employee of: KAN Research Institute, Inc. (subsidiary of Eisai Co., Ltd.), NAOTO ISHII Shareholder of: Eisai Co., Ltd., Employee of: KAN Research Institute, Inc. (subsidiary of Eisai Co., Ltd.), Toshio Imai Shareholder of: Eisai Co., Ltd., Employee of: KAN Research Institute, Inc. (subsidiary of Eisai Co., Ltd.), Tetsuo Mikami Speakers bureau: EA Pharma, Hiroyasu Nakano: None declared, Shinichi Kawai Grant/research support from: Nippon Zoki, Chugai, Ono, Ayumi, Hisamitu, Eisai, Japan Tobacco, Nippon Kayaku, Daiichi Sankyo, Astellas, Yutoku, and Mitsubishi Tanabe, Consultant for: Santen, Japan Tobacco, Speakers bureau: Ayumi, Chugai, Ono, Astellas, Pfizer, Celltrion, Toshihiro Nanki Grant/research support from: Chugai, Eisai, Takeda, Teijin, Eli Lilly, Bristol-Myers, AbbVie, Ono, Novartis, Asahikasei, Mitsubishi-Tanabe, Astellas, Ayumi, Pfizer, Daiichi Sankyo, Shionogi, Sanofi, Nippon Kayaku, Yutoku, Actelion, UCB, Bayer, Nihon Pharmaceutical., Consultant for: UCB, Eisai, Chugai, Ono, Gilead., Speakers bureau: Mitsubishi-Tanabe, Chugai, Eisai, Takeda, Astellas, Janssen, Eli Lilly, Ayumi, Pfizer, Asahikasei, Sanofi, Daiichi Sankyo, Otsuka, AbbVie, Ono, Teijin, Nippon Kayaku, UCB." @default.
• W2949461999 created "2019-06-27" @default.
• W2949461999 creator A5012122819 @default.
• W2949461999 creator A5014507927 @default.
• W2949461999 creator A5027763231 @default.
• W2949461999 creator A5041883149 @default.
• W2949461999 creator A5043121221 @default.
• W2949461999 creator A5044519948 @default.
• W2949461999 creator A5046736429 @default.
• W2949461999 creator A5056283302 @default.
• W2949461999 creator A5070436055 @default.
• W2949461999 creator A5072175179 @default.
• W2949461999 creator A5075139594 @default.
• W2949461999 creator A5081181665 @default.
• W2949461999 date "2019-06-01" @default.
• W2949461999 modified "2023-09-24" @default.
• W2949461999 title "THU0056 EFFECTS OF CX3CL1 INHIBITION ON MURINE BLEOMYCIN-INDUCED INTERSTITIAL PNEUMONIA" @default.
• W2949461999 cites W1625957341 @default.
• W2949461999 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1672" @default.
• W2949461999 hasPublicationYear "2019" @default.
• W2949461999 type Work @default.
• W2949461999 sameAs 2949461999 @default.
• W2949461999 citedByCount "0" @default.
• W2949461999 crossrefType "proceedings-article" @default.
• W2949461999 hasAuthorship W2949461999A5012122819 @default.
• W2949461999 hasAuthorship W2949461999A5014507927 @default.
• W2949461999 hasAuthorship W2949461999A5027763231 @default.
• W2949461999 hasAuthorship W2949461999A5041883149 @default.
• W2949461999 hasAuthorship W2949461999A5043121221 @default.
• W2949461999 hasAuthorship W2949461999A5044519948 @default.
• W2949461999 hasAuthorship W2949461999A5046736429 @default.
• W2949461999 hasAuthorship W2949461999A5056283302 @default.
• W2949461999 hasAuthorship W2949461999A5070436055 @default.
• W2949461999 hasAuthorship W2949461999A5072175179 @default.
• W2949461999 hasAuthorship W2949461999A5075139594 @default.
• W2949461999 hasAuthorship W2949461999A5081181665 @default.
• W2949461999 hasBestOaLocation W29494619991 @default.
• W2949461999 hasConcept C126322002 @default.
• W2949461999 hasConcept C12823836 @default.
• W2949461999 hasConcept C13373296 @default.
• W2949461999 hasConcept C142724271 @default.
• W2949461999 hasConcept C203014093 @default.
• W2949461999 hasConcept C2776232574 @default.
• W2949461999 hasConcept C2776694085 @default.
• W2949461999 hasConcept C2776914184 @default.
• W2949461999 hasConcept C2777077863 @default.
• W2949461999 hasConcept C31179232 @default.
• W2949461999 hasConcept C502942594 @default.
• W2949461999 hasConcept C71924100 @default.
• W2949461999 hasConcept C82321936 @default.
• W2949461999 hasConceptScore W2949461999C126322002 @default.
• W2949461999 hasConceptScore W2949461999C12823836 @default.
• W2949461999 hasConceptScore W2949461999C13373296 @default.
• W2949461999 hasConceptScore W2949461999C142724271 @default.
• W2949461999 hasConceptScore W2949461999C203014093 @default.
• W2949461999 hasConceptScore W2949461999C2776232574 @default.
• W2949461999 hasConceptScore W2949461999C2776694085 @default.
• W2949461999 hasConceptScore W2949461999C2776914184 @default.
• W2949461999 hasConceptScore W2949461999C2777077863 @default.
• W2949461999 hasConceptScore W2949461999C31179232 @default.
• W2949461999 hasConceptScore W2949461999C502942594 @default.
• W2949461999 hasConceptScore W2949461999C71924100 @default.
• W2949461999 hasConceptScore W2949461999C82321936 @default.
• W2949461999 hasLocation W29494619991 @default.
• W2949461999 hasOpenAccess W2949461999 @default.
• W2949461999 hasPrimaryLocation W29494619991 @default.
• W2949461999 hasRelatedWork W2550068855 @default.
• W2949461999 hasRelatedWork W2755631785 @default.
• W2949461999 hasRelatedWork W2808789066 @default.
• W2949461999 hasRelatedWork W2808879847 @default.
• W2949461999 hasRelatedWork W2808908470 @default.
• W2949461999 hasRelatedWork W2809222541 @default.
• W2949461999 hasRelatedWork W2809330699 @default.
• W2949461999 hasRelatedWork W2948044755 @default.
• W2949461999 hasRelatedWork W2948076684 @default.
• W2949461999 hasRelatedWork W2950163351 @default.
• W2949461999 hasRelatedWork W2950503305 @default.
• W2949461999 hasRelatedWork W2950949039 @default.
• W2949461999 hasRelatedWork W2952144267 @default.
• W2949461999 hasRelatedWork W2953125472 @default.
• W2949461999 hasRelatedWork W3033646365 @default.
• W2949461999 hasRelatedWork W3033868593 @default.
• W2949461999 hasRelatedWork W3035375314 @default.
• W2949461999 hasRelatedWork W3035377564 @default.
• W2949461999 hasRelatedWork W3035571563 @default.
• W2949461999 hasRelatedWork W3035704725 @default.
• W2949461999 isParatext "false" @default.
• W2949461999 isRetracted "false" @default.
• W2949461999 magId "2949461999" @default.
• W2949461999 workType "article" @default.